Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
An inverse agonist of estrogen-related receptor-γ (ERRγ), an orphan nuclear receptor encoded by E srrg, enhances sodium iodide symporter-mediated radioiodine uptake in anaplastic thyroid cancer (ATC) cells, thereby facilitating responsiveness to radioiodine therapy in vitro. We synthesized potent, selective, and orally bioavailable ERRγ-inverse agonists and evaluated their activity by analyzing in vitro pharmacology and absorption, distribution, metabolism, excretion, and toxicity profiles. X-ray crystallographic analysis of the ligand and ERRγ complex showed that 35 completely binds to the target protein (PDB 6A6K ). Our results showed improved radioiodine avidity in ATC cells through compound 35-mediated upregulation of iodide-handling genes, leading to enhanced responsiveness to radioiodine therapy in vitro. Importantly, in vivo I-positron emission tomography/computed tomography imaging revealed that 35 increases radioiodine avidity in CAL62 tumors. Collectively, these results demonstrated that 35 can be developed as a promising treatment for ERRγ-related cancer in the future.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acs.jmedchem.8b01296 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Discovery of an exquisitely selective WDR5 chemical probe accelerated by a high-quality DEL-ML Hit.
RSC Chem Biol
July 2025
Institute for Pharmaceutical Chemistry, Johann Wolfgang Goethe-University Max-von-Laue-Str. 9 D-60438 Frankfurt am Main Germany
Herein we present the rapid development of LH168, a potent and highly selective chemical probe for WDR5, streamlined by utilizing a DEL-ML (DNA encoded library-machine learning) hit as the chemical starting point. LH168 was comprehensively characterized in bioassays and demonstrated potent target engagement at the WIN-site pocket of WDR5, with an EC of approximately 10 nM, a long residence time, and exceptional proteome-wide selectivity for WDR5. In addition, we present the X-ray co-crystal structure and provide insights into the structure-activity relationships (SAR).
View Article and Find Full Text PDFMonoclonal Antibody 5F1 Modulates Formyl Peptide Receptor 1 Conformation for Transmembrane Signaling.
FASEB Bioadv
September 2025
Kobilka Institute of Innovative Drug Discovery, School of Medicine The Chinese University of Hong Kong Shenzhen Guangdong China.
Formyl peptide receptor 1 (FPR1) is a G protein-coupled receptor (GPCR) that mediates chemotaxis and bactericidal activities in phagocytes. The monoclonal antibody 5F1 is generated against full-length FPR1 and used widely for detection of FPR1 expression. This study aimed to characterize 5F1 for its functions.
View Article and Find Full Text PDFHarnessing the potential of phytochemicals to design anti-filarial molecules targeting the MurE enzyme of : a hierarchical virtual screening and molecular dynamics simulation study.
SAR QSAR Environ Res
August 2025
Structural Biology and Biocomputing Lab, Department of Bioinformatics, Alagappa University, Karaikudi, India.
, a causative agent of lymphatic filariasis, relies on its endosymbiont for survival. MurE ligase, a key enzyme in peptidoglycan biosynthesis, serves as a promising drug target for anti-filarial therapy. In this study, we employed a hierarchical virtual screening pipeline to identify phytochemical inhibitors targeting the MurE enzyme of the endosymbiont of (MurE).
View Article and Find Full Text PDFDiscovery of a selective alpha-kinase 1 inhibitor for the rare genetic disease ROSAH syndrome.
Nat Commun
September 2025
Shanghai Yao Yuan Biotechnology Ltd (Drug Farm), Shanghai, China.
ROSAH (retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and headache) syndrome is a rare genetic disease caused by variants in alpha-kinase 1 (ALPK1) resulting in downstream pro-inflammatory signaling mediated by the TIFA/TRAF6/NF-κB pathway. Here, we report the design of an ALPK1 inhibitor, DF-003, with pharmacokinetic properties suitable for daily oral dosing. In biochemical assays, DF-003 potently inhibits human ALPK1 (IC = 1.
View Article and Find Full Text PDFSpatial Distortion-Engineered Cationic Ru-Covalent Organic Framework Overcoming Aggregation-Caused Quenching for Synergistic Photodynamic/Photothermal Anti-Infective Therapy.
ACS Appl Mater Interfaces
September 2025
Affiliated Hospital of Shandong Second Medical University, Shandong Second Medical University, Weifang, Shandong 261053, P.R. China.
Decades of antibiotic misuse have spurred an antimicrobial resistance crisis, creating an urgent demand for alternative treatment options. Although phototherapy has therapeutic potential, the efficacy of the most advanced photosensitizers (PS) is essentially limited by aggregation-induced quenching, which significantly reduces their therapeutic effect. To address these challenges, we developed a cationic metallocovalent organic framework (CRuP-COF) via a solvent-mediated dual-reaction synthesis strategy.
View Article and Find Full Text PDF